France
Neurochlore, founded in 2011 and headquartered in France, is on a groundbreaking journey to tackle developmental brain disorders. The company's focus is on creating therapeutic strategies specifically aimed at ameliorating conditions like Autism Spectrum Disorders (ASD). With its slogan, "Understanding and Treating Developmental Brain Disorders," Neurochlore signals its profound commitment to this cause.
The company has strategically aligned itself with global leaders in developmental neurobiology and neurological disorders. By engaging in extensive collaborations with drug developers and neuro-pediatric clinical experts, Neurochlore is innovating therapeutic applications for its patented diuretic treatment for ASD. A successful monocentric study has paved the way for multicentric phase II trials, and a promising double-blind randomized phase III study is on the horizon.
Funded in part by the Bettencourt Schueller Foundation, their fundamental research leverages large-scale animal models to study GABAergic and glutamatergic currents. Their last investment was a Non Equity Assistance deal by Incubateur Impulse as of 01 April 2021.
